AJANTA PHARMA, Novartis AG, Cipla Inc. Strides Pharma Science Limited. are Dominating the Global Malaria Treatment Market in 2019

Global Malaria Treatment Market is expected to grow with the CAGR of 6.1% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-malaria-treatment-market

Global malaria treatment market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in global malaria treatment market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio. For instance, in April 2019, WANECAM consortium (West African Network for Clinical Trials of Antimalarial Drugs) and Europe collaborated with the Novartis AG and Medicines for Malaria Venture (MMV) to develop its compound KAF156 in combination with a new formulation of lumefantrine. The fundamental motive of partnership is to advance the development of a new anti-malarial therapy as well as strengthening clinical trial development capabilities in Africa.

AJANTA PHARMA and Novartis AG is the dominating player in the malaria treatment market. The other key players existing in the market are Actiza Pharmaceutical Private Limited, AdvaCare Pharma, Amneal Pharmaceuticals LLC., Hikma Pharmaceuticals PLC, Ipca Laboratories Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Zydus Cadila,  Cipla Inc., Bliss GVS Pharma Ltd., GeoVax, MMV, Sumaya Biotech, Taj Pharmaceuticals Limited, VLP Therapeutics, OSIVAX, Lupin Pharmaceuticals, Inc. (a subsidiary of LUPIN)Lupin Pharmaceuticals, Inc., Strides Pharma Science Limited, sanofi-aventis U.S. LLC (a subsidiary of Sanofi)sanofi-aventis U.S. LLC, among others.

Malaria Treatment Market


AJANTA PHARMA headquarter is in Mumbai, India. Company is focusing on building strong brands across the markets. Moreover company is exclusively concentrating on development of generic and specialty formulations in different therapeutic segments. Additionally company is focusing sales force on the ground in these markets by creating separate divisions to focus on various therapies.  The company has business segments including pharmaceutical and related products, in these pharmaceutical and related products is the market focused segment.

  • In 2017, AJANTA PHARMA’s Dahej facility receives the successful USFDA approval. This approval has helped the company to gain the company presence in the U.S. market. Moreover, it has elevated the company revenue growth.

The company has wide presence across Asia-Pacific, Middle East and Africa, North America and others. The company also has various subsidiary companies such as Ajanta Pharma Inc. (Philippines), Ajanta Pharma Inc. (USA), Ajanta Pharma Limited (Nigeria), Ajanta Pharma Mauritius Limited (Mauritius) and others.

Novartis AG 

Novartis AG founded in the year 1996, headquartered in Basel, Switzerland. Company is focusing on developing a broad and consistent pipeline of off-patent launches across key geographies. Moreover company is exclusively concentrating on advanced therapy platforms and data science. Furthermore company is focusing on research and development activities there on expanding the scale and scope of their early clinical development and later-stage clinical trial operations to help accelerate the development of new medicines. The company has business segments including innovative medicines, sandoz, in these innovative medicines is the market focused segment. The company has wide product categories which are Afinitor Disperz/Votubia, Afinitor/Votubia, Aimovig, Arzerra, Beovu, Cibacen, Ciprodex, Comtan, Cosentyx, Diovan, Riamet, among others, in which Riamet is the market focused categories.

  • In September 2019, Novartis AG announced the multiyear collaboration agreement with Microsoft. The fundamental aim of this collaboration is to transform medicines discovering, developing and commercializing process by utilizing leverage data & Artificial Intelligence (AI). This collaboration has anticipated the company presence in global market.

The company has presence across Asia-Pacific, Europe, Middle East and Africa, North America, Latin America and others. The company also has various subsidiary companies such as Novartis Pharmaceuticals Canada Inc. (Canada), Beijing Novartis Pharma Co., Ltd (China), Novartis de Colombia S.A. (Colombia), Novartis Pharma NV (Belgium), Sandoz GmbH (Austria), among others.

Cipla Inc.

Cipla Inc. founded in 1935, headquartered in Mumbai, India. Company is focusing on differentiated launches along with expansion of respiratory franchise (approval for Albuterol and filing of gAdvair). Moreover company is exclusively centrating on managing manufacturing and supply chain – both back-end supplies and front-end logistics. The company operates its business through pharmaceuticals and new venture in which pharmaceuticals is the market focused segment. The company has various product categories that are our therapies, API in which API is the market focused category.

  • In July 2017, Cipla Inc. and its partner Medicines for Malaria Venture (MMV) announced the launch of 100 mg Artesunate Rectocaps/Rectal Artesunate Suppositories (RAS). Usage of this launched product is life-saving, pre-referral intervention for the management of severe malaria in young children. This product launch has escalated the company revenue growth.

The company has presence in the Asia-Pacific, Europe, North America and others. The company has also various subsidiaries that are Cipla Pharmaceuticals Limited (India), Cipla (China) Pharmaceutical Co. Limited, Cipla (Jiangsu) PharmaceuticalCo, Limited, Cipla (EU) Limited, Goldencross Pharma Limited (India), among others.